Alkermes plc. (ALKS) Stock Analysis and Metrics

Alkermes

NASDAQ: ALKS

$52.88 ▼ -0.09 (-0.17%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.78 Bn

P/E291.94

P/S5.62

Div. Yield0.00

Total Debt (Qtr)1.51 Bn

Revenue Growth (1y) (Qtr)28.19

Add ratio to table…

About

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines for neuroscience disorders. The company markets proprietary products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia, LYBALVI for schizophrenia and bipolar I disorder, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. Alkermes also maintains a robust pipeline of clinical and preclinical candidates targeting similar indications, notably Alixorexton an oral orexin 2 receptor agonist being evaluated for narcolepsy type 1 and idiopathic hypersomnia. Headquartered in Ireland, Alkermes operates a corporate office and research center in Massachusetts and a manufacturing facility in Wilmington, Ohio. Following the completion of the Avadel acquisition in February 2026, the company added a dedicated commercial organization for LUMRYZ to its U. S. operations.

Alkermes generates revenue primarily through direct sales of its proprietary medicines in the United States. Product sales of ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and LUMRYZ constitute the core of its top line. In addition, the company receives royalty payments from licensed products that incorporate its technologies, such as the long acting INVEGA products and RISPERDAL CONSTA commercialized by Janssen, and VUMERITY marketed by Biogen worldwide. Alkermes also earns manufacturing revenues from its collaborations with Janssen and Biogen for the production of microspheres and drug substance. According to its public disclosures, royalties from Janssen represented approximately 9% of consolidated revenue in 2025, 17% in 2024 and 31% in 2023, while royalties from Biogen accounted for about 9% in 2025, 9% in 2024 and 8% in 2023. The remaining revenue is derived from product sales and contract manufacturing arrangements with third parties.

Alkermes holds a differentiated position in the biopharmaceutical industry due to its proprietary technology platforms that enable differentiated dosing and improved patient outcomes. These platforms include LINKERX for extended release injectable antipsychotics, NANOCRYSTAL for nanoparticle formulation of poorly water soluble compounds, MICROPUMP for oral controlled release systems, and injectable extended release microsphere technology for sustained drug delivery. The company’s intellectual property portfolio provides long term protection for its marketed products, with patents extending into the 2030s and 2040s for key assets such as ARISTADA, LYBALVI, VIVITROL and LUMRYZ. LUMRYZ additionally benefits from seven years of orphan drug exclusivity in the United States for both adult and pediatric narcolepsy populations. Alkermes competes with large pharmaceutical companies such as Janssen Pharmaceuticals, Otsuka Pharmaceutical, Eli Lilly and Company, Indivior plc, Teva Pharmaceutical Industries and Biogen, as well as numerous generic manufacturers. Competitive advantages stem from its specialized focus on central nervous system disorders, its ability to deliver once monthly or once at bedtime dosing regimens, and its established commercial infrastructure in the United States.

Alkermes serves a diverse customer base that includes pharmaceutical wholesalers, specialty distributors, specialty pharmacies and treatment providers who supply its medicines to healthcare professionals and patients. In the United States, key wholesalers such as McKesson Corporation, Cardinal Health and Cencora (formerly AmerisourceBergen) account for a substantial share of product distribution. LUMRYZ is distributed through a limited network comprising CVS Specialty Pharmacy, Accredo, Optum Specialty Pharmacy and Assist Rx. The company’s sales force sizes reflect its commercial focus, with approximately 105 representatives dedicated to VIVITROL, around 435 representatives covering ARISTADA, ARISTADA INITIO and LYBALVI, and about 60 representatives supporting LUMRYZ following the Avadel acquisition. Additionally, Alkermes’ licensees Janssen and Biogen act as downstream customers for its manufacturing and royalty streams, receiving finished product or active pharmaceutical ingredient under their respective agreements.

Investment Thesis

▲ Bull case

Alkermes is positioned to capture significant value from its differentiated orexin platform, particularly through Alixorexton, which has demonstrated robust clinical differentiation in narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) via the Vibrance-2 and Vibrance-3 studies. The company's strategic expansion into ADHD and fatigue indications using ALKS 7290 and ALKS 4510 leverages the same mechanistic advantage—targeting wakefulness pathways without the abuse potential or cardiovascular risks of stimulants—creating a broad pipeline beyond sleep disorders. Preclinical data showing ALKS 7290 outperforming stimulants in attention and impulsivity models, combined with ongoing Phase Ib/II trials, suggest a first-in-class opportunity in ADHD where current therapies face adherence and tolerability challenges. The market is underestimating the potential for Alkermes to become a leader in multiple neuroscience indications by applying its orexin expertise to adjacent areas with high unmet need, supported by early clinical signals and regulatory engagement.
The recent positive top-line results from the REVITALYZ study for LUMRYZ in idiopathic hypersomnia (IH) represent a materially underappreciated catalyst, as it establishes a clear regulatory path for an sNDA submission by end-2026 and potential launch in early 2028, despite the existing settlement restriction. LUMRYZ’s differentiated once-nightly dosing, favorable patient mix (new, switching, returning oxybate users), and strong early traction—3,600 patients on therapy after just 10 weeks post-acquisition—indicate durable demand and pricing power. The company’s guidance of $350–370 million in LUMRYZ net sales for 2026 already reflects only six weeks of Avadel contribution, implying a full-year run rate significantly above current estimates. With Alkermes now owning both LUMRYZ and Alixorexton, it controls a comprehensive sleep medicine franchise that can cross-sell to sleep specialists, creating a powerful commercial engine ahead of Alixorexton’s potential approval.
Alkermes’ financial flexibility is stronger than perceived due to conservative purchase price accounting adjustments following the Avadel acquisition. The company reduced its expected 2026 LUMRYZ inventory step-up charge from $150 million to $105 million and intangible amortization from $95–105 million to $75–85 million, directly improving GAAP net loss and EBITDA outlook. Combined with $538 million in cash and investments, a share repurchase authorization of $172 million, and expectations to pay down the $1.525 billion term loan quickly via operating cash flow, Alkermes has ample liquidity to fund its expanding pipeline without dilution. The adjusted EBITDA guidance of over $370 million for 2026—driven by $1.7 billion in expected revenue—provides a substantial war chest to advance Alixorexton through Phase III, initiate ADHD and fatigue trials, and pursue lifecycle opportunities for LUMRYZ, all while maintaining investment-grade credit metrics.

Alkermes is positioned to capture significant value from its differentiated orexin platform, particularly through Alixorexton, which has demonstrated robust clinical differentiation in narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) via the Vibrance-2 and Vibrance-3 studies. The company's strategic expansion into ADHD and fatigue indications using ALKS 7290 and ALKS 4510 leverages the same mechanistic advantage—targeting wakefulness pathways without the abuse potential or cardiovascular risks of stimulants—creating a broad pipeline beyond sleep disorders. Preclinical data showing ALKS 7290 outperforming stimulants in attention and impulsivity models, combined with ongoing Phase Ib/II trials, suggest a first-in-class opportunity in ADHD where current therapies face adherence and tolerability challenges. The market is underestimating the potential for Alkermes to become a leader in multiple neuroscience indications by applying its orexin expertise to adjacent areas with high unmet need, supported by early clinical signals and regulatory engagement.
The recent positive top-line results from the REVITALYZ study for LUMRYZ in idiopathic hypersomnia (IH) represent a materially underappreciated catalyst, as it establishes a clear regulatory path for an sNDA submission by end-2026 and potential launch in early 2028, despite the existing settlement restriction. LUMRYZ’s differentiated once-nightly dosing, favorable patient mix (new, switching, returning oxybate users), and strong early traction—3,600 patients on therapy after just 10 weeks post-acquisition—indicate durable demand and pricing power. The company’s guidance of $350–370 million in LUMRYZ net sales for 2026 already reflects only six weeks of Avadel contribution, implying a full-year run rate significantly above current estimates. With Alkermes now owning both LUMRYZ and Alixorexton, it controls a comprehensive sleep medicine franchise that can cross-sell to sleep specialists, creating a powerful commercial engine ahead of Alixorexton’s potential approval.
Alkermes’ financial flexibility is stronger than perceived due to conservative purchase price accounting adjustments following the Avadel acquisition. The company reduced its expected 2026 LUMRYZ inventory step-up charge from $150 million to $105 million and intangible amortization from $95–105 million to $75–85 million, directly improving GAAP net loss and EBITDA outlook. Combined with $538 million in cash and investments, a share repurchase authorization of $172 million, and expectations to pay down the $1.525 billion term loan quickly via operating cash flow, Alkermes has ample liquidity to fund its expanding pipeline without dilution. The adjusted EBITDA guidance of over $370 million for 2026—driven by $1.7 billion in expected revenue—provides a substantial war chest to advance Alixorexton through Phase III, initiate ADHD and fatigue trials, and pursue lifecycle opportunities for LUMRYZ, all while maintaining investment-grade credit metrics.

▼ Bear case

Alkermes faces significant near-term headwinds from generic competition in its core franchises, particularly VIVITROL, where Teva’s anticipated 2027 entry could undermine the durable narrative management promotes. Despite claims of VIVITROL’s uniqueness due to manufacturing and commercial complexity, the product relies on a monthly injectable format vulnerable to biosimilar or generic substitution, especially if Teva achieves parity in efficacy and safety. The company’s refusal to model additional gross-to-net favorability beyond Q1 suggests awareness of impending pricing pressure, and the alcohol dependence market’s fragmentation across state payer systems limits scalability. Meanwhile, LYBALVI’s gross-to-net adjustments are already widening into the mid-30s, signaling eroding pricing power in psychiatry, where competition from newer atypical antipsychotics and long-acting injectables is intensifying. These pressures could constrain cash flow generation just as R&D spending ramps up for Alixorexton and new orexin programs, creating a funding gap for pipeline advancement.
The orexin pipeline, while promising, carries substantial clinical and regulatory risks that are not being sufficiently discounted by the market. Alixorexton’s Phase III Brilliance program in narcolepsy type 1 and 2, though supported by strong Phase II data, remains vulnerable to failure in pivotal trials—particularly given the historical difficulty of demonstrating separation from placebo in hypersomnolence disorders. The company’s reliance on secondary endpoints like fatigue and cognition for differentiation may not translate to label claims, limiting commercial appeal. Furthermore, the expansion into ADHD and fatigue indications is highly speculative: ALKS 7290’s monotherapy approach in ADHD lacks validation in patients with intact orexin tone, and the assumption that it can match or exceed stimulant efficacy without their side effects is unproven in humans. The fatigue program in MS and Parkinson’s is even earlier stage, with no clinical data yet, and faces steep hurdles in proving meaningful improvement over existing symptomatic therapies in neurodegenerative diseases where symptom burden is multifactorial.
Alkermes’ balance sheet strain from the Avadel acquisition poses a material risk to financial flexibility, despite management’s optimistic debt paydown timeline. The $1.525 billion in term loans due in 2031 requires sustained high free cash flow to refinance or repay, yet the company’s adjusted EBITDA guidance of $370+ million for 2026 leaves little margin for error after accounting for $110–120 million in quarterly R&D, $210–220 million in SG&A, and ongoing integration costs. The $775 million in cash used for the acquisition, combined with $28 million in Q1 share repurchases, has already reduced the cash buffer, and any delay in LUMRYZ uptake or Alixorexton milestones could force difficult choices between pipeline investment, debt reduction, and shareholder returns. Additionally, the REMS restrictions on LUMRYZ and the potential for abuse/misuse monitoring burdens could limit real-world adoption, especially in idiopathic hypersomnia where prescriber familiarity with oxybates is low, constraining the upside from the REVITALYZ success beyond current expectations.

Alkermes faces significant near-term headwinds from generic competition in its core franchises, particularly VIVITROL, where Teva’s anticipated 2027 entry could undermine the durable narrative management promotes. Despite claims of VIVITROL’s uniqueness due to manufacturing and commercial complexity, the product relies on a monthly injectable format vulnerable to biosimilar or generic substitution, especially if Teva achieves parity in efficacy and safety. The company’s refusal to model additional gross-to-net favorability beyond Q1 suggests awareness of impending pricing pressure, and the alcohol dependence market’s fragmentation across state payer systems limits scalability. Meanwhile, LYBALVI’s gross-to-net adjustments are already widening into the mid-30s, signaling eroding pricing power in psychiatry, where competition from newer atypical antipsychotics and long-acting injectables is intensifying. These pressures could constrain cash flow generation just as R&D spending ramps up for Alixorexton and new orexin programs, creating a funding gap for pipeline advancement.
The orexin pipeline, while promising, carries substantial clinical and regulatory risks that are not being sufficiently discounted by the market. Alixorexton’s Phase III Brilliance program in narcolepsy type 1 and 2, though supported by strong Phase II data, remains vulnerable to failure in pivotal trials—particularly given the historical difficulty of demonstrating separation from placebo in hypersomnolence disorders. The company’s reliance on secondary endpoints like fatigue and cognition for differentiation may not translate to label claims, limiting commercial appeal. Furthermore, the expansion into ADHD and fatigue indications is highly speculative: ALKS 7290’s monotherapy approach in ADHD lacks validation in patients with intact orexin tone, and the assumption that it can match or exceed stimulant efficacy without their side effects is unproven in humans. The fatigue program in MS and Parkinson’s is even earlier stage, with no clinical data yet, and faces steep hurdles in proving meaningful improvement over existing symptomatic therapies in neurodegenerative diseases where symptom burden is multifactorial.
Alkermes’ balance sheet strain from the Avadel acquisition poses a material risk to financial flexibility, despite management’s optimistic debt paydown timeline. The $1.525 billion in term loans due in 2031 requires sustained high free cash flow to refinance or repay, yet the company’s adjusted EBITDA guidance of $370+ million for 2026 leaves little margin for error after accounting for $110–120 million in quarterly R&D, $210–220 million in SG&A, and ongoing integration costs. The $775 million in cash used for the acquisition, combined with $28 million in Q1 share repurchases, has already reduced the cash buffer, and any delay in LUMRYZ uptake or Alixorexton milestones could force difficult choices between pipeline investment, debt reduction, and shareholder returns. Additionally, the REMS restrictions on LUMRYZ and the potential for abuse/misuse monitoring burdens could limit real-world adoption, especially in idiopathic hypersomnia where prescriber familiarity with oxybates is low, constraining the upside from the REVITALYZ success beyond current expectations.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password